GlaxoSmithKline P.L.C. has won swift approval from the federal government to produce and sell a booster vaccine against Haemophilus influenzae type b, which should help eliminate shortages of the shot against the deadly disease.
GlaxoSmithKline P.L.C. has won swift approval from the federal government to produce and sell a booster vaccine against Haemophilus influenzae type b, which should help eliminate shortages of the shot against the deadly disease.